b-cell lymphoma study: anti-CD19-DM4 immunoconjugate - SAR3419

[Guest guest]

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-Positive

B-Cell Non-Hodgkin's Lymphoma

An antibody, similar to rituxan, that binds to cd19, with a cytotoxic agent

attached. ~ Karl

http://clinicaltrials.gov/ct2/show/NCT00796731

anti-CD19-DM4 immunoconjugate SAR3419

An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to

the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with

potential antineoplastic activity.

Anti-CD19-DM4 conjugate SAR3419 targets the cell surface antigen CD19, found on

a number of B-cell-derived cancers. Upon antibody/antigen binding and

internalization, the immunoconjugate releases DM4, which binds to tubulin and

disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of

cell division and cell growth of CD19-expressing tumor cells.

=